Urosin Mechanism of Action

Pharmacology: Atenolol is a β₁-selective (cardioselective) adrenergic receptor-blocking agent without membrane-stabilising and intrinsic sympathomimetic (partial agonist) activities.
The action of atenolol has been demonstrated by: Reduction in resting and exercise heart rate and cardiac output; reduction in systolic and diastolic blood pressure at rest and on exercise; inhibition of isoproterenol-induced tachycardia; and reduction in reflex orthostatic tachycardia.
Pharmacokinetics: Atenolol is rapidly but incompletely absorbed from the gastrointestinal tract. 40-50% are excreted in the urine unchanged and the rest are excreted in the feces mostly as unabsorbed drug. In healthy adults, peak plasma of 1-2 mcg/mL is achieved at 2-4 hrs after 200-mg oral administration. Its plasma half-life is 6-7 hrs. It is well distributed in most tissues except in brain and CSF. Atenolol crosses the placenta and diffuses to breast milk. About 5-15% are bound to plasma proteins.